Publications
387
Citations
17,351
Est. group size
~3
Recurring co-author estimate
Active years
33
Publishing since 1994
Nikolai Petrovsky's research focuses on developing and testing vaccine adjuvants (substances that boost immune responses) and immunotherapies for infectious diseases and allergies, including influenza, COVID-19, and mosquito-borne and parasitic infections. Much of the work involves preclinical testing in animals and early-phase clinical trials of vaccines using adjuvants such as Advax-CpG, alongside work on allergy treatments like immunotherapy for pollen allergies. This research could suit students interested in vaccine design, immunology, and translational clinical testing.
Publication output grew substantially from 2017 to a peak around 2021, then gradually declined toward a steadier pace of roughly 15-20 papers per year in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Design and Synthesis of New Pyrazolo[1,5‐ <i>c</i> ]quinazolin‐5‐amines as Potential TLR7/8 Modulators
ChemMedChem · 2026
- Target product profiles for treatments to delay or prevent symptomatic Alzheimer’s disease
Nature Medicine · 2026
- Featured Cover
Clinical & Experimental Allergy · 2026
- Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9
UNC Libraries · 2026
- Ultra-short recombinant Art v 1 immunotherapy induces rapid immune modulation in mugwort allergy: A Phase I trial
Allergology International · 2026
- Magnetoencephalography Reveals Neuroprotection of COVID-19 Vaccination in Nonhuman Primates
Vaccines · 2026
- Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9
Journal of Controlled Release · 2025
- Intranasal monoclonal antibodies to mugwort pollen reduce allergic inflammation in a mouse model of allergic rhinitis and asthma
Frontiers in Immunology · 2025
- Virus-like particle-based vaccines targeting the <i>Anopheles</i> mosquito salivary protein TRIO
mSphere · 2025
- Evaluation of safety, immunogenicity, and efficacy of inactivated reverse-genetics-based H5N8 highly pathogenic avian influenza virus vaccine with various adjuvants via parenteral and mucosal routes in chickens
Frontiers in Immunology · 2025
- A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18–45 years of age
Vaccine · 2025
- Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted recombinant hemagglutinin seasonal quadrivalent influenza vaccine
Vaccine · 2025
- Immunogenicity and safety study of a single dose of SpikoGen® vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults
Vaccine · 2025
- Advax®-adjuvanted inactivated influenza vaccine provides accelerated protection of mice via early induction of an influenza-specific IgM response
Vaccine · 2025
- One Health adjuvant selection for vaccines against zoonotic infections
Exploration of Medicine · 2025
- Vaccine×23
- Scientific Reports×9
- Figshare×9
- bioRxiv (Cold Spring Harbor Laboratory)×9
- npj Vaccines×8
- Yuan Pu
Medicine · The Ohio State University
- Hadi M. Yassine
Medicine · Indiana University
- Mahesh KC
Medicine · The Ohio State University
- Amanda M. Williams
Medicine · The Ohio State University
- Cong Zeng
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile